FRACTYL HEALTH INC
GUTSNASDAQTrading Snapshot
- Day Range
- $0.86 – $0.91
- 52-Week Range
- $1.02 – $29.34
- Volume (shares)
- 579,724
- Avg Volume (shares)
- —
- Shares Outstanding
- 13.3M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 152.6x
- EPS (TTM)
- $-2.07
- Dividend Yield
- —
- Dilution (1yr)
- +214.6%
FRACTYL HEALTH INC
GUTS
StockOtter · stockotter.spaceAbout FRACTYL HEALTH INC
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns or
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) and certain officers. The class ac
GUTS CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Fractyl (NASDAQ: GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
NEW YORK--(BUSINESS WIRE)---- $GUTS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. ("“Fractyl” or the “Company”) (NASDAQ: GUTS)
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm
Fractyl Health, Inc. (NASDAQ: GUTS) shareholders should email fletcher@fmoorelaw.com NEW YORK, Oct. 19, 2026 /PRNewswire/ -- What is the Investigation About? On January 29, 2026, before the market opened, Fractyl Health,
GUTS DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fract
Deadline Alert: Fractyl Health, Inc. Investors Have Until October 20, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds
Class action covers investors who bought Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026; complaint alleges the company failed to disclose material adverse facts Class action covers investor